Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methyldopa
Drug ID BADD_D01425
Description Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent.[A231784] It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals.[A1499] Methyldopa exists in two isomers D-α-methyldopa and L-α-methyldopa, which is the active form.[A232224] First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency. Since then, methyldopa was largely replaced by newer, better-tolerated antihypertensive agents;[A231784] however, it is still used as monotherapy [L32614] or in combination with [hydrochlorothiazide].[L32619] Methyldopa is also available as intravenous injection, which is used to manage hypertension when oral therapy is unfeasible and to treat hypertensive crisis.[L32624]
Indications and Usage For use in the treatment of hypertension.
Marketing Status Prescription; Discontinued
ATC Code C02AB01
DrugBank ID DB00968
KEGG ID D00405
MeSH ID D008750
PubChem ID 38853
TTD Drug ID D0BA6T
NDC Product Code 15894-0038; 42185-7001; 16729-031; 52423-0100; 16729-030; 67628-3001
Synonyms Methyldopa | alpha-Methyldopa | alpha Methyldopa | alpha-Methyl-L-Dopa | alpha Methyl L Dopa | Alphamethyldopa | Meldopa | Methyldopate | Dopegyt | Dopergit | Dopegit | Sembrina | Apo-Methyldopa | Apo Methyldopa | Dopamet | Aldomet | Hydopa | Nu-Medopa | Nu Medopa
Chemical Information
Molecular Formula C10H13NO4
CAS Registry Number 555-30-6
SMILES CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Antinuclear antibody positive13.06.01.003--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.01.01.003--Not Available
Connective tissue disorder15.06.01.006--Not Available
Coombs test positive13.01.01.002--Not Available
Infestation11.09.01.001; 23.09.05.001--Not Available
Lactation disorder21.05.02.004; 18.06.02.003--
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Erectile dysfunction21.03.01.007; 19.08.04.001--
Respiratory disorder neonatal22.11.01.002; 18.04.09.0020.007059%Not Available
Blood disorder01.05.01.004--Not Available
Psychotic disorder19.03.01.002--
Hepatobiliary disease09.01.08.003--Not Available
Lichenoid keratosis23.01.01.004--Not Available
Bone marrow failure01.03.03.005--
Liver injury12.01.02.003; 09.01.07.022--Not Available
Low birth weight baby18.04.02.0030.065884%Not Available
Acute kidney injury20.01.03.0160.004706%
Foetal growth restriction18.03.01.0020.021177%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.007059%Not Available
Cerebral haemorrhage neonatal17.08.01.048; 24.07.04.024; 18.04.16.0010.001841%Not Available
Ductus arteriosus stenosis foetal24.03.03.027; 03.07.09.0060.007059%Not Available
Neonatal respiratory distress syndrome22.11.02.010; 18.04.10.0030.004706%Not Available
Primary hyperaldosteronism24.08.04.006; 14.05.04.010; 05.01.01.0070.004706%Not Available
Renal failure neonatal20.01.03.024; 18.04.01.0190.004706%Not Available
Small for dates baby18.04.02.0020.007059%Not Available
Kidney enlargement20.01.06.0030.004706%Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages